Home Loans
Personal Loans
SME Loans
Business Loans - Udyog Plus 
Loan Against Securites
Loan Against Property
Mutual Fund
Stock and Securities
Wealth
Portfolio Management Services
Pension Funds
Life Insurance
Health Insurance
Wellness Solutions
Pay Bills
Pay for anything
Pay Anyone
Pay on Call
Payment Lounge
Credit Cards
1800-270-7000-
Our Products
-
Self Care
- Downloads
- Learnings
- About Us
-
More
-
Shareholders
-
Shareholders
-
Updates
-
-
Wealth Calculator
-
Link to ODR
-
Shareholders
ABC Solution 
Loans
Insurance
AppStore
PlaystoreAditya Birla Sun Life AMC Limited
Aditya Birla Sun Life AMC Limited
Investment Objective
The investment objective of the scheme is to provide long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
This product is suitable for investors who are seeking
- Long term capital growth
- Investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India
Product Videos:
English | Hindi | Gujarati | Marathi | Tamil | Telugu | Kannada | Malayalam
Fund Details
- Fund Type - Open-Ended
- Category - Equity
- Sub-Category - Sectoral
- Min Investment - Rs. 1000/-
- Fund Manager - Mr. Dhaval Shah & Mr. Dhaval Joshi
- Latest NAV - 29.8 (as on 26-Jul-2024)
- Inception Date - Jul 11, 2019
View Full Details
Fund Performance
Trailing Return
Funds are bucketed on various parameters with respect to other funds in their category.
*Annualized returns are displayed for 1 year and above.
*Annualized returns are displayed for 1 year and above.
Annualized Returns
Fund Management
-
Mr. Dhaval Shah
Total Experience : 16 years
View Full ProfileDhaval Shah is a Fund Manager and Senior Analyst with Aditya Birla Sun Life AMC Limited (ABSLAMC). He has an overall experience of more than 16 years in Indian equity markets and has been a part of ABSLAMC since 2015.
Prior to ABSLAMC, Dhaval has worked with Reliance Capital Asset Management Ltd., Morgan Stanley Investment Management and Edelweiss Securities Ltd.
Dhaval is an MBA in Finance from Mumbai University. He is also a CFA Charter Holder. -
Mr. Dhaval Joshi
Total Experience : 15 years
View Full ProfileDhaval Joshi has an overall experience of 15 years in equity research and investments. Prior to joining Aditya Birla Sun Life AMC Limited, he was associated with Sundaram Mutual Fund (India) Ltd. for around 5 years. He has also worked as a research analyst with Emkay Global Financial Services and Asit C Mehta Investment Intermediates Ltd.
View Fund Managed by
Load More
Total Schemes managed by {fundmanagername} is {fundmanagerfundcount}
Different plans shall have a different expense structure. The performance details provided herein are of (regular / direct) plan.
Different plans shall have a different expense structure. The performance details provided herein are of (regular / direct) plan.
To check an all-time best return rate for equity funds, check how they've performed in the last 3 or 5 years.
Check your investment performance
Use this tool by entering any amount you would have invested to calculate how much it would be worth today.
I had invested
as an
CALCULATE RETURN
Rs
Minimum Amount is Rs 500
in
Select the type of Fund
Fund
Select the Fund name
as an
Select Lumpsum or frequency of SIP
starting on
Select the date invested
Your Investment Summary
- Investment AmountRs 5000
- Initial units per month 29.5
- Current valueRs 50,000
- Current NAV value 260
- Current Units 30
-
XIRR
5.10%
Internal rate of return or annualized yield for a schedule of cash flows occurring at irregular intervals.
-
Benchmark XIRR
8%
Internal Rate of return or annualized yield for a schedule of cash flows occurring at irregular intervals for respective benchmark index.
Fund Summary
Entry Load
Exit Load
Load Comments
NIL
For redemption/switch-out of units on or before 30 days from the date of allotment: 1.00 % of applicable NAV.
For redemption/switch-out of units after 30 days from the date of allotment: Nil
Highlights
- Long term capital growth
- Investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India
Fund Summary
Healthcare is an important part of our living. Right from birth till the end of life, we depend on healthcare. The cutting-edge advancements in Health & Pharma industry are not only giving us a better life but also increasing life expectancy. Add to that, growing awareness & incomes which are spear-heading greater use of healthcare solutions. The manufacturing driven Indian Pharmaceutical companies are gaining ground in exports. India is the largest producer of Generic drugs in the world. A domestic and an export led demand of Pharma & Healthcare services draws attention to its imminent rise. The Indian Pharmaceutical Industry having grown almost 3 times, from USD 12.6bn2 in 2009 to USD 38bn3 in 2018, constitutes a network of over 3,000 pharma companies housing about 10,500 manufacturing facilities. The Indian health care industry which stood at USD 110bn in 20174, includes in its ambit a wide network of hospitals, labs and diagnostics, medical equipment and supplies, medical insurance and emerging segments such as wellness products, contract research and biotechnology services. The Indian pharmaceutical and health sector is expected to achieve double digit growth figures in the years to come. This fund aims to help investors take advantage of this emerging sector by investing in pharma and healthcare companies which are well diversified business models with an optimal business mix across all main geographies – India, US & Emerging Markets. This fund would focus on areas like pharmaceuticals and formulations, speciality chemicals, hospitals and diagnostics, wellness products and other ancillary healthcare segments. Benchmark is S&P BSE Health Care
Aditya Birla Sun Life Pharma and Healthcare Fund
(An Open Ended equity scheme investing in Pharma and Healthcare Services Sector)
This product is suitable for investors who are seeking*
- Long term capital growth
- Investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India
*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.
Show More
Disclaimer
*Second Income/Regular Income/Monthly Income is not assured and is subject to availability of distributable surplus. Dividend distribution in the form of regular income to individual investors is subject to dividend distribution tax (DDT) of 13.5188% which is deducted by the fund house. For individual nature of tax implications, investors are requested to consult their tax advisors before investing.
**The portfolio of the scheme is subject to changes within the provisions of the Scheme Information Document. Please refer to the Scheme Information Document for asset allocation, investment strategy, and risk factors.
+Investors should note that declaration of dividends is at the discretion of Trustees and subject to availability of distributable surplus and there is no guarantee or assurance on the frequency or quantum of dividends. The NAV of the scheme pursuant to a payout of the dividend would fall to the extent of the payout and statutory levy (if applicable). For individual nature of tax implications, investors are requested to consult their tax advisor before investing.